Abstract | BACKGROUND & AIMS: METHODS: To induce liver fibrosis, rats underwent bile duct ligation and treatment with sirolimus (2mg/kg), everolimus (3mg/kg), tacrolimus (1mg/kg), and cyclosporin A (10mg/kg) daily for 5 weeks. Fibrosis, inflammation, and portal pressure were evaluated by histology, hydroxyproline levels, morphometry, hemodynamics, and hepatic gene expression. RESULTS: CONCLUSIONS:
|
Authors | Eleonora Patsenker, Vreni Schneider, Monika Ledermann, Hans Saegesser, Christoph Dorn, Claus Hellerbrand, Felix Stickel |
Journal | Journal of hepatology
(J Hepatol)
Vol. 55
Issue 2
Pg. 388-98
(Aug 2011)
ISSN: 1600-0641 [Electronic] Netherlands |
PMID | 21168455
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Calcineurin Inhibitors
- Immunosuppressive Agents
- RNA, Messenger
- Triglycerides
- Cyclosporine
- Everolimus
- mTOR protein, rat
- TOR Serine-Threonine Kinases
- Matrix Metalloproteinases
- Sirolimus
- Tacrolimus
|
Topics |
- Animals
- Bile Ducts
- Calcineurin Inhibitors
- Cyclosporine
(pharmacology)
- Disease Progression
- Everolimus
- Fatty Liver
(drug therapy, metabolism)
- Immunosuppressive Agents
(pharmacology)
- Ligation
- Liver Cirrhosis, Experimental
(drug therapy, genetics, pathology, physiopathology)
- Male
- Matrix Metalloproteinases
(metabolism)
- Non-alcoholic Fatty Liver Disease
- Portal Pressure
(drug effects)
- RNA, Messenger
(genetics, metabolism)
- Rats
- Rats, Wistar
- Sirolimus
(analogs & derivatives, pharmacology)
- TOR Serine-Threonine Kinases
(antagonists & inhibitors)
- Tacrolimus
(pharmacology)
- Triglycerides
(metabolism)
|